Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)

Withdrawn before enrolling · Phase 2

Conditions studied: Infantile Hemangiomas

In brief

The purpose of this study is to determine whether Timolol 0.5% Gel Forming Solution is safe and effective in promoting wound healing of infantile ulcerated hemangiomas compared with standard conservative management with topical antibiotic.

Key facts

Study ID

NCT01408056

Run by

Children's Hospital of Philadelphia

People needed

0

Starts

2011-02-01

Expected to finish

2014-01-01

Last updated by the study team

2014-01-17

Who can join

Age: 0 and older, up to 1. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infants weighing between 4-12kg
• Infants with corrected gestational age 44 weeks - 8 months of age
• Infant with an ulcerated hemangioma
• Informed consent

You may not qualify if…

• Ulceration larger than 16cm2
• Ulcerated hemangioma with active bleeding or infection at time of enrollment
• Disease threatening hemangioma meeting criteria for oral propranolol
• Previous treatment with topical/oral corticosteroid or propranolol
• Medical history of congenital heart disease with decreased cardiac output, stroke/cerebral vasculopathy, active reactive airway disease or metabolic disorder
• History of an allergic reaction to Mupirocin or Timolol
• Currently taking medication that would interact with beta-blockers

Where it is running

• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.